New Nordic Healthbrands Valuation
Is N9X undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of N9X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate N9X's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate N9X's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for N9X?
Other financial metrics that can be useful for relative valuation.
What is N9X's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 102.22m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.2x |
Enterprise Value/EBITDA | -19.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does N9X's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.5x | ||
ENGKAH Eng Kah Corporation Berhad | 1x | n/a | RM 44.9m |
HRP Harper Hygienics | 0.2x | n/a | zł40.5m |
932 Shunten International (Holdings) | 0.3x | n/a | HK$80.8m |
AROM Aroma AD | 0.4x | n/a | лв15.6m |
N9X New Nordic Healthbrands | 0.2x | n/a | €102.2m |
Price-To-Sales vs Peers: N9X is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.5x).
Price to Earnings Ratio vs Industry
How does N9X's PE Ratio compare vs other companies in the European Personal Products Industry?
Price-To-Sales vs Industry: N9X is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Personal Products industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is N9X's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate N9X's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.